Mathes Company Inc. sell 5,200 shares of Pfizer Inc. (NYSE:PFE)

Vaseline3 weeks ago

0 4 minutes read

Mathes Company Inc. reduced its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 13.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,300 shares of the biopharmaceutical company’s stock after selling 5,200 shares during the quarter. The holdings of Mathes Company Inc. in Pfizer were worth $904,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP boosted its stake in shares of Pfizer by 4.9% in the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after purchasing an additional 11,099,024 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Pfizer by 3.2% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 71,794,056 shares of the biopharmaceutical company’s stock valued at $2,008,798,000 after buying an additional 2,241,609 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of Pfizer by 1.8% during the 2nd quarter. Van ECK Associates Corp now owns 16,104,088 shares of the biopharmaceutical company’s stock valued at $450,593,000 after buying an additional 290,760 shares during the period. of shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Pfizer by 3.3% in the second quarter. Federated Hermes Inc. now owns 14,923,545 shares of the biopharmaceutical company’s stock valued at $417,561,000 after purchasing an additional 470,003 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its position in Pfizer by 2.4% in the second quarter. Envestnet Asset Management Inc. now owns 10,260,067 shares of the biopharmaceutical company’s stock worth $287,077,000 after buying an additional 238,850 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s shares.

Analysts set new price targets

Several research firms have issued reports on PFE. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.54, according to MarketBeat.

Want more great investment ideas?

Check out Pfizer’s latest stock report

Pfizer price performance

Shares of PFE stock opened at $29.75 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86, and a quick ratio of 0.60. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.11. The firm has a 50-day moving average of $29.33 and a 200-day moving average of $28.19. The company has a market cap of $168.58 billion, a P/E ratio of -495.75, a PEG ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE – Get Free Report ) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. In the same quarter last year, the business posted EPS of $0.67. On average, sell-side analysts estimate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer announces dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were given a $0.42 dividend. This represents a dividend of $1.68 on an annualized basis and a dividend yield of 5.65%. The ex-dividend date was Friday, July 26. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer profile

(Free report)

Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United States, Europe and internationally. The company offers drugs and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine and women’s health under the brands Eliquis, Nurtec ODT/Vydura, Zavzpret and Premarin; infectious diseases with unmet medical needs under the family brands Prevnar, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; and the prevention and treatment of COVID-19 and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.